HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

House Has Slim Boost For FDA FY2023 Spending, But Wants Slimmer Budget Document From Agency

Executive Summary

Appropriations Committee publishes FY2023 spending bill and report FDA day before it votes on the legislation. It recommends increasing FDA’s budget by less than $400m from its current appropriation to $6.48bn.

You may also be interested in...



Senate Proposes Smaller Boost Than House For FDA FY2023 Appropriation

A  proposed budget from the US Senate appropriations committee would fund the FDA's device activities at $663m for fiscal 2023, marking a modest increase from 2022 but a drop from House and administration requests. 

Senate Proposes Smaller Boost Than House For FDA FY2023 Appropriation

Senate Appropriations Committee proposes $1.185bn to CFSAN and $2.19bn to CDER, both levels short of House appropriators passed in June. FDA requested $30.36m in user fees from monograph drugs but no amount was specified in Senate draft bill.

Honey Sachets Are Latest Sweet Spot For Selling Products With Undisclosed ED Drugs In US

FDA's warnings to four companies selling honey sachets containing undisclosed ED ingredients are latest examples of businesses marketing noncompliant products because the agency doesn't have sufficient funding to regulate the market, says University of Connecticut pharmacy professor Michael White.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS152653

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel